CD274 and melanoma: With these advantages, MUSE loaded with MT-CRISPR/Cas9 demonstrated effective elimination of PD-L1 and CD47 in tumor cells and activated both innate and adaptive antitumor immunity, thereby significantly improving overall survival in mouse model of melanoma with no detectable off-target effects.